Maravai LifeSciences Holdings

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The Protein Detection segment is engaged in manufacturing and selling labeling and visual detection reagents to scientific research customers for their tissue-based protein detection and characterization needs. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Maravai LifeSciences reports record earnings, eyes sustainable growth strategies

Maravai LifeSciences delivered strong financial performance in Q4 2022 and full year 2022, with record revenue and robust margins, supported by strategic acquisitions and diversified revenue streams.
While facing challenges such as geopolitical risks and margin fluctuations, the company is well-positioned to capitalize on growth opportunities in the cell and gene therapy market, driven by customer-centric strategies and market stability.
By focusing on sustainable growth, ESG initiatives, and customer adaptation, Maravai aims to maintain its competitive edge and drive long-term value creation for shareholders and stakeholders.
The company's commitment to innovation, market expansion, and operational efficiency underscores its resilience and potential for continued success in the evolving biotechnology landscape.

Maravai LifeSciences reports solid Q1 results amidst market challenges

Maravai LifeSciences delivered strong financial performance in Q1 2023, driven by core business strength and innovation.
While facing challenges in the biotech market and revenue decline, the company is strategically positioned for growth.
Opportunities lie in customer adoption, inorganic growth, and recovery in key markets like China.

Maravai LifeSciences adjusts revenue guidance amidst industry demand weakness

Maravai LifeSciences faces near-term challenges with revenue guidance adjustments but maintains confidence in long-term growth prospects. The company is strategically positioned in mRNA and nucleic acid chemistry, focusing on innovation and cost management strategies to drive future success.

Maravai LifeSciences reports strong Q3 earnings, eyes biotech market growth

Maravai LifeSciences Holdings reported solid Q3 performance, focusing on cost reductions and strategic investments. Despite challenges in customer conversations and limited visibility for 2024, the company remains optimistic about growth opportunities in key markets.

Maravai LifeSciences posts robust Q4 results and targets diversified growth

Maravai LifeSciences delivered strong Q4 results and expects continued growth in 2024 with a more diversified customer base.
The company's focus on innovation, efficiency, and customer commitment positions it well for future success.
While facing revenue challenges in Q1, Maravai's performance in Biologic Safety Testing segment provides stability.
Margin expansion tied to top-line growth and CleanCap technology adoption present promising opportunities for the company.

Maravai LifeSciences reports solid Q1 performance amidst growth strategies

Maravai LifeSciences Holdings navigates Q1 2024 with solid revenue, strategic partnerships, and a focus on growth and innovation.
Despite debt challenges, the company's strong cash position, cost reduction efforts, and margin improvement targets signal resilience and adaptability.
Opportunities in GMP product growth, M&A activities, and customer journey insights position Maravai for continued success and market leadership.
Addressing challenges in debt management, cost optimization, and revenue forecasting will be key to sustaining growth and profitability.

Maravai LifeSciences maintains solid financials and strategic partnerships for growth

Maravai LifeSciences demonstrates financial stability and growth potential with steady revenue guidance.
Operational successes at Flanders facilities and new product offerings enhance market competitiveness.
Challenges in managing costs and maximizing profitability require strategic decision-making.
Strategic partnerships and focus on sustainability present opportunities for market expansion and innovation.

Maravai LifeSciences reports Q3 revenue, lowers 2024 guidance, eyes acquisitions

Maravai LifeSciences Holdings faced challenges in Q3 2024 but showcased strengths in its Nucleic Acid Production segment and strategic initiatives. The company is focused on growth opportunities in mRNA technologies and expanding its product portfolio through acquisitions and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2022 financial and operating results after the market closes on Wednesday, February 22, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Maravai LifeSciences to Host Earnings Conference Call on Wednesday, February 22, 2023

Beam Therapeutics

Novavax

These beaten-down stocks could be poised for major rebounds.

3 Great Growth Stocks Down 20% or More to Buy Now

Moderna

Vertex Pharmaceuticals

All three are protected by sales of in-demand products, with more on the way.

3 Biopharma Stocks That Could Help Make You a Fortune

Maravai announces plans for William “Trey” Martin, III to serve as President of its Biologics Safety Testing Segment and its expectation that he will then assume the role of Maravai's CEO in July 2023

Maravai LifeSciences Announces Updated CEO Leadership Transition Plans

SAN DIEGO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced it ranked 270 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 28th year.

Maravai LifeSciences Named to the 2022 Deloitte Technology Fast 500™ List of Fastest-Growing Companies in North America

Altra Industrial Motion

Carvana

Generac Holdings

Norwegian Cruise Line

Olaplex Holdings

Vaxcyte

PTC Therapeutics

Patterson-UTI Energy

Mid-cap companies lie in between the slower growth large-cap stocks and the faster-growth small-cap businesses.

These Were The Five Best And Worst Performing Mid-Cap Stocks In October 2022

SOUTHPORT, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cygnus Technologies , part of Maravai LifeSciences (Maravai) (NASDAQ: MRVI), the leading assay and services provider for the detection and characterization of process-related impurities in biopharmaceuticals, announced today the launch of the MockV® RVLP Kit. This kit enables bioprocess scientists to quantify the removal of Retrovirus-Like Particles (RVLPs) produced endogenously by Chinese Hamster Ovary (CHO) cell lines during biopharmaceutical manufacturing. The kit includes a highly purified and concentrated stock solution of RVLPs along with the necessary reagents for accurate and reliable RVLP quantification.

New Kit Predicts Retroviral Particle Clearance in Biopharmaceutical Manufacturing

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q3 2022 Results Conference Call November 2, 2022 5:00 PM ET Company Participants Deb Hart - Head of Investor Relations Carl Hull - Interim Chief Executive Officer Kevin Herde - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley John Sourbeer - UBS Paul Knight - KeyBanc Madeline Mollman - William Blair Michael Ryskin - Bank of America Dan Arias - Stifel Dan Leonard - Credit Suisse Brandon Couillard - Jefferies Operator Greetings, and welcome to Maravai LifeSciences Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2022 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 15.63% and 1.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Maravai LifeSciences Holdings, Inc. (MRVI) Q3 Earnings Beat Estimates

It's positioned to benefit from the emergence of a new, long-term trend in biopharma.

This Fallen Growth Stock Is Still a Wall Street Favorite: Here's Why

Maravai has seen a real boom from the pandemic. Sales could likely see pressure in 2023, even as underlying non-pandemic related growth seems solid.

Maravai LifeSciences: Establishing The Diagnosis

Maravai LifeSciences and Recently-Appointed CEO Trey Martin Vigorously Defending Against Suit Maravai LifeSciences and Recently-Appointed CEO Trey Martin Vigorously Defending Against Suit

Maravai LifeSciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation

SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2022 financial and operating results after the market closes on Wednesday, November 2, 2022, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 2, 2022

SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that its Board of Directors has appointed William “Trey” Martin, III as its chief executive officer (CEO). Mr. Martin comes to Maravai most recently from Danaher Corporation, where he was the Senior Vice President of New Business, Genomic Medicine. Maravai's first CEO and co-founder Carl Hull will directly support Mr. Martin during this leadership transition and will remain with Maravai as Executive Chairman of the Board where he will continue to guide the company's long-term strategy.

Maravai LifeSciences Announces CEO Leadership Transition

TriLink now offers GMP-grade N1-Methyl-Pseudouridine-5'-Triphosphate, a critical raw material for mRNA manufacturing, allowing researchers to accelerate their drug discovery and development timelines and US-source their supply chain TriLink now offers GMP-grade N1-Methyl-Pseudouridine-5'-Triphosphate, a critical raw material for mRNA manufacturing, allowing researchers to accelerate their drug discovery and development timelines and US-source their supply chain

TriLink BioTechnologies, Part of Maravai LifeSciences, Expands its mRNA Raw Material Offering with the First GMP-grade Modified Nucleoside-Triphosphate Product

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Deb Hart - Head of Investor Relations Carl Hull - Chief Executive Officer Kevin Herde - Chief Financial Officer Conference Call Participants Max Smock - William Blair & Company Matthew Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Paul Knight - KeyBanc Capital Markets Inc. Michael Ryskin - Bank of America Brandon Couillard - Jefferies Group LLC John Sourbeer - UBS Group AG Deb Hart Thank you, Vikram, and good afternoon, everyone. Thanks for joining us on our Second Quarter 2022 Earnings Call.

Maravai LifeSciences Holdings, Inc. (MRVI) CEO Carl Hull on Q2 2022 Results - Earnings Call Transcript

Mattel

3 of the Best Bear Market Buys for August

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 20% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Maravai LifeSciences Holdings, Inc. (MRVI) Q2 Earnings and Revenues Beat Estimates

SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, August 4th, by Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), please note that a variety of changes have been made throughout the release. These includes the wording of the subheadline, the wording and figure in the fourth bullet point,  the wording and figures in the last paragraphs of each Financial Results section, and the Explanatory Notes numbers (9) and (10). The corrected release follows:

CORRECTION: Maravai Lifesciences Reports Second Quarter 2022 Financial Results

Record First Half Revenue, EBITDA, Adjusted EBITDA and EPS Record First Half Revenue, EBITDA, Adjusted EBITDA and EPS

Maravai Lifesciences Reports Second Quarter 2022 Financial Results

Maravai LifeSciences Holdings, Inc. (MRVI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Maravai LifeSciences Holdings, Inc. (MRVI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Axsome Therapeutics

Novocure

Each of these stocks is ready for a rebound.

3 Beaten-Down Stocks That Could Soar in the Second Half of 2022

SAN DIEGO, July 19, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2022 financial and operating results after the market closes on Thursday, August 4, 2022, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 4, 2022

Appoints Dr. Kate Broderick as Senior Vice President of Research and Development Appoints Dr. Kate Broderick as Senior Vice President of Research and Development

TriLink BioTechnologies, part of Maravai LifeSciences, Expands R&D Leadership Team

DOD to fund planned manufacturing expansion and to prepare the U.S. for a rapid response to the next pandemic as part of Industrial Base Expansion DOD to fund planned manufacturing expansion and to prepare the U.S. for a rapid response to the next pandemic as part of Industrial Base Expansion

News for Maravai LifeSciences Holdings Stock (MRVI)